Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

DARK SECRETS: Why is autolus therapeutics stock trading higher on tuesday - The Real Truth

Scientist,Pipetting,At,A,Biomedical,Laboratory

The U.K.’s National Institute for Health and Care Excellence (NICE) published on Tuesday draft guidance recommending Autolus Therapeutics plc’s (NASDAQ:AUTL) Aucatzyl (obecabtagene autoleucel, or obe-cel) for use in the National Health Service (NHS) for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).

• AUTL stock is showing exceptional strength. Get the market research here.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.